We are live on
!
Find out more
CAC
Cowen and Company Portfolio holdings
AUM
$2.97B
1-Year Est. Return
105.26%
This Fund
S&P 500
This Quarter
Est. Return
+5.02%
1 Year Est. Return
+105.26%
3 Year Est. Return
+120.06%
5 Year Est. Return
+670.57%
10 Year Est. Return
–
AUM
$1.05B
AUM Growth
+$9.85M
(+0.95%)
Cap. Flow
+$95.1M
Cap. Flow
% of AUM
9.1%
Top 10 Holdings %
Top 10 Hldgs %
50%
Holding
874
New
223
Increased
214
Reduced
73
Closed
220
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$54.9M |
| 2 |
Immunocore
IMCR
|
+$48.2M |
| 3 |
ARK Innovation ETF
ARKK
|
+$41.6M |
| 4 |
TWTR
Twitter, Inc.
TWTR
|
+$36.7M |
| 5 |
RNAM
Avidity Biosciences
RNAM
|
+$29.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Relmada Therapeutics
RLMD
|
+$23.6M |
| 2 |
PSTH
Pershing Square Tontine Holdings, Ltd.
PSTH
|
+$19M |
| 3 |
RBAC
RedBall Acquisition Corp.
RBAC
|
+$12.5M |
| 4 |
Sumitomo Mitsui Financial
SMFG
|
+$12.1M |
| 5 |
Stoke Therapeutics
STOK
|
+$11.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.11% |
| 2 | Financials | 8.03% |
| 3 | Materials | 6.97% |
| 4 | Technology | 3.58% |
| 5 | Industrials | 3.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
ARK Innovation ETF
ARKK
$5.59B
| $131M | 12.57% |
3,483,400
+933,400
| +37% | +$41.6M |
|
2
Sylvamo
SLVM
$1.48B
| $72.9M | 6.97% |
2,150,000
| – | – |
|
|
RNAM
3
DELISTED
Avidity Biosciences
RNAM
| $61.9M | 5.92% |
3,788,366
+1,524,216
| +67% | +$29.2M |
|
|
4
Immunocore
IMCR
$1.69B
| $47.5M | 4.54% |
+1,011,670
| New | +$48.2M |
|
5
Establishment Labs
ESTA
$2.71B
| $45.7M | 4.37% |
836,654
| – | – |
|
6
Adicet Bio
ACET
$82M
| $34.7M | 3.32% |
152,703
-33
| -0% | -$8.38K |
|
7
FTAI Aviation
FTAI
$20.8B
| $28.1M | 2.69% |
1,874,508
-128,546
| -6% | -$2.22M |
|
|
CUTR
8
DELISTED
Cutera, Inc.
CUTR
| $27.2M | 2.6% |
596,213
-92
| -0% | -$4.2K |
|
9
Innoviz Technologies
INVZ
$92.3M
| $26.4M | 2.53% |
5,066,390
+295,000
| +6% | +$1.41M |
|
|
10
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$15.9B
| $20.8M | 1.99% |
+726,608
| New | +$54.9M |
|
11
Energy Transfer Partners
ET
$70.2B
| $20.7M | 1.98% |
1,875,000
+440,000
| +31% | +$4.9M |
|
|
12
Sumitomo Mitsui Financial
SMFG
$165B
| $20.2M | 1.93% |
3,677,105
-1,999,500
| -35% | -$12.1M |
|
13
Fulcrum Therapeutics
FULC
$236M
| $19M | 1.82% |
2,347,989
-37,896
| -2% | -$271K |
|
|
AVDL
14
DELISTED
Avadel Pharmaceuticals
AVDL
| $18.7M | 1.79% |
3,732,778
| – | – |
|
|
SCPL
15
DELISTED
SciPlay Corporation Class A Common Stock
SCPL
| $17.3M | 1.66% |
1,471,246
+125,000
| +9% | +$1.56M |
|
16
Rocket Pharmaceuticals
RCKT
$336M
| $16M | 1.53% |
999,588
-412
| -0% | -$6.43K |
|
|
PEGR
17
DELISTED
Project Energy Reimagined Acquisition Corp. Class A Ordinary Share
PEGR
| $14.8M | 1.41% |
1,500,000
| – | – |
|
|
HCVIU
18
DELISTED
Hennessy Capital Investment Corp. VI Unit
HCVIU
| $14.6M | 1.39% |
1,500,000
| – | – |
|
19
Apyx Medical
APYX
$173M
| $12.8M | 1.23% |
2,854,841
+36,500
| +1% | +$261K |
|
|
CTLP
20
DELISTED
Cantaloupe
CTLP
| $11.5M | 1.1% |
3,855,240
+892,052
| +30% | +$4.89M |
|
|
21
Stoke Therapeutics
STOK
$1.81B
| $9.88M | 0.94% |
769,169
-740,451
| -49% | -$11.8M |
|
22
Playtika
PLTK
$1.49B
| $9.15M | 0.88% |
+975,000
| New | +$11.2M |
|
23
Tarsus Pharmaceuticals
TARS
$2.53B
| $8.94M | 0.86% |
522,329
-12,195
| -2% | -$194K |
|
|
JNCE
24
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $8.54M | 0.82% |
3,647,430
+804,281
| +28% | +$2.85M |
|
|
25
Relmada Therapeutics
RLMD
$535M
| $8.01M | 0.77% |
216,441
-850,413
| -80% | -$23.6M |
|
Similar funds
CIP
PWLP
FPCG
SI
BC
FTDI
CIM
PRO
Cowen and Company's Q3 2022 Portfolio in Review
As of Q3 2022, Cowen and Company held 874 positions worth $1.05B, up 0.95% from $1.04B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Cowen and Company deployed $95.1M of net new capital in Q3 2022, opening 223 new positions and adding to 214 existing holdings. Its largest new stake was iShares iBoxx $ High Yield Corporate Bond ETF: 726,608 shares worth $20.8M.
By sector, the portfolio is most concentrated in Healthcare at 34% of assets, up from 29% a quarter earlier, followed by Financials and Materials.
On the sell side, the largest reduction was Relmada Therapeutics, an estimated $23.6M trimmed.
- Cowen and Company's largest Q3 2022 buy was iShares iBoxx $ High Yield Corporate Bond ETF: 726,608 shares worth $20.8M.
- Cowen and Company added most to ARK Innovation ETF in Q3 2022, an estimated $41.6M increase.
- Cowen and Company's biggest Q3 2022 reduction was Relmada Therapeutics, cutting an estimated $23.6M.
- Cowen and Company fully exited Pershing Square Tontine Holdings, Ltd. in Q3 2022, selling an estimated $19M.
- Cowen and Company's ten largest holdings make up 50% of its $1.05B portfolio in Q3 2022.
- Cowen and Company opened 223 new positions and closed 220 in Q3 2022.
- Cowen and Company's portfolio value rose 0.95% quarter-over-quarter to $1.05B.
Based on Cowen and Company's 13F filing for Q3 2022, filed 14 Nov 2022.